BiotechTube
Home/Pipeline/Endoxifen

Endoxifen

Breast Cancer

Phase 1/2Active

Key Facts

Indication
Breast Cancer
Phase
Phase 1/2
Status
Active
Company
Alchem Laboratories

About Alchem Laboratories

Alchem Laboratories is a long-established, private biotech firm with a dual focus on infectious disease therapeutics and a robust contract development and manufacturing (CDMO) service for clinical-stage APIs. Its core capabilities include custom synthesis, assay development, and high-throughput screening (HTS), supported by leadership with deep experience in drug delivery and government contracting. While its public pipeline data shows activity in oncology and other areas, its stated mission centers on advancing antiviral and antibody treatments, positioning it at the intersection of internal R&D and external service provision.

View full company profile

Therapeutic Areas

Infectious DiseaseOncology

Other Breast Cancer Drugs

DrugCompanyPhase
Antifibrotic Therapy ProgramMeCo DiagnosticsPre-clinical
inPROBE for HER2SDS OpticClinical Investigation
APA-1000 Breast Thermotherapy SystemMedifocusPhase III
Unnamed Breast Cancer ProgramClick TherapeuticsPilot/Phase 2
Lerociclib (Lerocliclib)Chemogenics BioPharmaPhase 3
AT-017Asieris PharmaceuticalsNot Specified
CDK2 inhibitorAcelleraPre-clinical
NP-G2-044Novita PharmaceuticalsPhase 2a
GCT-007Global Cancer TechnologyResearch
NDESContinuity BiosciencesPre-clinical
INP12InnoUpClinical
Dedicated Breast Radiotherapy SystemEhmet HealthCommercial